ReNeuron Shares Jump As Lead Cell Line Shows Further Potential
ReNeuron Shares Jump As Lead Cell Line Shows Further Potential
Read moreFri, 26th Apr 2019 12:09
ReNeuron Shares Jump As Lead Cell Line Shows Further Potential
Read moreReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial
Read more(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.
Read more(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a
Read more(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.
Read more(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said
Read more(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at
Read more(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.
Read moreLONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also
Read more(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.
Read moreLONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up
Read moreLONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in
Read moreLONDON (Alliance News) - ReNeuron Group PLC on Tuesday said it has signed an exclusive licence agreement for the development, manufacture and commercialisation of its CTX and hRPC cell therapy in
Read more(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.
Read more